Report Detail

Publication Date: November 12, 2021
Purchase Price: $4,750.00
View Report Gallery

Interventional Cardiology: Implantable Pacemaker Products

In 2020, the global market for implantable pacemaker products totaled nearly $3.9bn, with dual-chamber products accounting for nearly 75% of sales. Over the forecast period covered by this report, single-chamber pacemaker devices are expected to experience greater growth than the dual-chamber market, advancing at a CAGR of approximately 6.8%. Drivers include a growing prevalence of cardiovascular disease due to the aging population, the development of leadless pacemaker systems, and expanded indications. Additionally, there is strong evidence of a correlation between COVID-19 and the development of atrial arrythmias. Given the scale of the pandemic, combined with this trend, there is the strong possibility of a short-term increase in patients requiring pacemakers. Limiters include device cost, lack of long-term data for leadless technology, and lack of trained operators and facilities in certain geographic regions. Another major short-term concern is that rising geopolitical tensions combined with the effects of the COVID-19 pandemic have resulted in a series of bottlenecks hampering the production and distribution of the chips used in pacemakers and other medical devices. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for pacemaker systems for the US, five major European markets, Japan, and Rest of World markets for the years 2019–25.

Back to the top Back to the top